RPDC concept

Concept for routine practice data collection – nogapendekin alfa inbakicept (urinary bladder carcinoma)

Status
Status: Commission work started
Project no.
A26-68
Last updated

Project details

Project no.
A26-68
Commission
Commission awarded on 04.06.2026 by the Federal Joint Committee (GBA).
Report type
RPDC concept
Status
Commission work started
Department/Division
Drug Assessment
Topic
Cancer
Note

Routine practice data collection (RPDC): Review of the study protocol and statistical analysis plan

In the case of new drugs that have entered the health care system via a special marketing authorization or as a drug for the treatment of a rare disease, the study data at the time of marketing authorization are usually not very informative for the early benefit assessment. As in the present case, the GBA can require the pharmaceutical company to collect routine practice data, including the associated analysis, for the benefit assessment. The pharmaceutical company has to submit a study protocol and a statistical analysis plan for the RPDC. IQWiG reviews these documents on behalf of the GBA.

Connected Projects

  1. Search for disease registries

    Non-muscle invasive urinary bladder carcinoma; assessment according to §35a Social Code Book V; search for disease registries

    Project no.
    I25-03
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form